



Atty. Dkt. No. 040283-0183
Appln. No. 09/622,544

#8
125
11/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sarkis Barret KALINDJIAN et al.

Title: Histamine H3 Receptor Ligands

Appl. No.: 09/622,544

Filing Date: 10/13/2000

Examiner: B. Kifle

Art Unit: 1624

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This communication responds to the Office Action dated September 26, 2001, a response to which is due by the shortened statutory deadline of **October 26, 2001**.

REMARKS

The Examiner required an Election of Species between the compounds embraced by the formula of claim 1.

In response to the requirement for election of species, Applicants provisionally elect as a single disclosed species, with traverse, the compound of Example 71, N-(4-Chlorobenzyl)-N-(7-pyrrolidin-1-yl-heptyl)-guanidine bis-hydrochloride, for the purpose of initial examination. Claims 1, 4, 6-13, 20, 24-25, and 28 are readable on the elected species. Should claims embracing the elected species be found allowable, the generic claims should be examined, along with remaining species.

Applicants respectfully traverse the requirement of election of species for the following reasons.